Tags

Type your tag names separated by a space and hit enter

Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study.
Eur Heart J. 1998 Jul; 19 Suppl H:H42-7.EH

Abstract

Low high density lipoprotein (HDL) cholesterol, elevated triglycerides, or a combination of both, carries an increased risk of coronary heart disease (CHD). The benefit of therapy that increases serum HDL cholesterol concentrations and lowers triglyceride concentrations on the reduced incidence of myocardial infarctions and mortality has not been unequivocally demonstrated in healthy persons or patients with CHD. The Bezafibrate Infarction Prevention (BIP) study randomized men and women, with CHD and with total serum cholesterol 180 - 250 mg. dl-1, low density lipoprotein (LDL) cholesterol < or = 180 mg. dl-1 (< or = 160 mg. dl-1 below age 50 years), HDL cholesterol < or = 45mg. dl-1 and triglycerides < or = 300 mg. dl-1, to bezafibrate retard (400 mg once daily) or placebo. In addition to its effect on the lipids, this drug significantly lower plasma fibrinogen. The demographic, clinical and biochemical characteristics and existing cardiovascular therapy at baseline of 3122 patients randomized onto the study are presented here. A comparison is made with other on-going or recently published secondary prevention studies of lipid modification in CHD patients.

Authors+Show Affiliations

Neufeld Cardiac Research Institute, Sheba Medical Center, Tel Hashomer, Israel.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

9717065

Citation

Goldbourt, U, et al. "Baseline Characteristics of Patients Participating in the Bezafibrate Infarction Prevention (BIP) Study." European Heart Journal, vol. 19 Suppl H, 1998, pp. H42-7.
Goldbourt U, Brunner D, Behar S, et al. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study. Eur Heart J. 1998;19 Suppl H:H42-7.
Goldbourt, U., Brunner, D., Behar, S., & Reicher-Reiss, H. (1998). Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study. European Heart Journal, 19 Suppl H, H42-7.
Goldbourt U, et al. Baseline Characteristics of Patients Participating in the Bezafibrate Infarction Prevention (BIP) Study. Eur Heart J. 1998;19 Suppl H:H42-7. PubMed PMID: 9717065.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study. AU - Goldbourt,U, AU - Brunner,D, AU - Behar,S, AU - Reicher-Reiss,H, PY - 1998/8/26/pubmed PY - 1998/8/26/medline PY - 1998/8/26/entrez SP - H42 EP - 7 JF - European heart journal JO - Eur Heart J VL - 19 Suppl H N2 - Low high density lipoprotein (HDL) cholesterol, elevated triglycerides, or a combination of both, carries an increased risk of coronary heart disease (CHD). The benefit of therapy that increases serum HDL cholesterol concentrations and lowers triglyceride concentrations on the reduced incidence of myocardial infarctions and mortality has not been unequivocally demonstrated in healthy persons or patients with CHD. The Bezafibrate Infarction Prevention (BIP) study randomized men and women, with CHD and with total serum cholesterol 180 - 250 mg. dl-1, low density lipoprotein (LDL) cholesterol < or = 180 mg. dl-1 (< or = 160 mg. dl-1 below age 50 years), HDL cholesterol < or = 45mg. dl-1 and triglycerides < or = 300 mg. dl-1, to bezafibrate retard (400 mg once daily) or placebo. In addition to its effect on the lipids, this drug significantly lower plasma fibrinogen. The demographic, clinical and biochemical characteristics and existing cardiovascular therapy at baseline of 3122 patients randomized onto the study are presented here. A comparison is made with other on-going or recently published secondary prevention studies of lipid modification in CHD patients. SN - 0195-668X UR - https://www.unboundmedicine.com/medline/citation/9717065/Baseline_characteristics_of_patients_participating_in_the_Bezafibrate_Infarction_Prevention__BIP__Study_ L2 - https://medlineplus.gov/heartattack.html DB - PRIME DP - Unbound Medicine ER -